Current Liabilities decreased faster than Viridian Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Viridian Therapeutics Inc 's Quick Ratio to 11.31, above Viridian Therapeutics Inc average Quick Ratio.

Within Medical Laboratories industry 3 other companies have achieved higher Quick Ratio than Viridian Therapeutics Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 185 to 305.

Explain Quick Ratio?
How much Cash & cash equivalents VRDN�s has?
What are VRDN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VRDN Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Mar 31 2025) Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	8.87 %	72.11 %	38.99 %	29.41 %	80.61 %
Y / Y Cash & cash equivalent Change	-5.2 %	19.78 %	-30.72 %	-0.22 %	65 %
Quick Ratio MRQ	11.31	9.37	6.34	15.56	12.99
VRDN's Total Ranking	# 305	# 185	# 382	# 193	#
Seq. Current Liabilities Change	-26.72 %	39.45 %	51.61 %	-29.73 %	15.85 %
Seq. Cash & cash equivalent Change	-11.54 %	106.15 %	-38.27 %	-15.79 %	11.77 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 4
Healthcare Sector	# 135
Overall Market	# 305

Quick Ratio Statistics
High	Average	Low
20.18	8.32	0.73
(Mar 31 2024)		(Dec 31 2016)

Financial Statements
Viridian Therapeutics Inc 's Current Liabilities	$ 52 Millions	Visit VRDN's Balance sheet
Viridian Therapeutics Inc 's Cash & cash equivalent	$ 586 Millions	Visit VRDN's Balance sheet
Source of VRDN's Sales		Visit VRDN's Sales by Geography

Cumulative Viridian Therapeutics Inc 's Quick Ratio

VRDN's Quick Ratio for the trailling 12 Months

VRDN Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	36.87 %	56.02 %	54.81 %	53.19 %	41.13 %
Y / Y Cash & cash equivalent TTM Growth	-3.08 %	10.94 %	28.91 %	60.26 %	94.51 %
Quick Ratio TTM	10.11	10.48	11.65	13.59	14.28
Total Ranking TTM	# 3342	# 1797	# 2105	# 2624	#
Seq. Current Liabilities TTM Growth	2.08 %	17.14 %	8.97 %	5.03 %	16.37 %
Seq. Cash & cash equivalent TTM Growth	-1.52 %	5.43 %	-6.61 %	-0.05 %	12.73 %

Quick ratio ranking by company, industry and sector >> Back to VRDN Financial Strength Comparisons >> Go to Compare VRDN Quick Ratio to its Competitors

On the trailing twelve months basis Due to cut in Current Liabilities in the Q1 2026 to $51.81 millions, cumulative Quick Ratio decreased to 10.11 above the VRDN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 3 other companies have achieved higher Quick Ratio than Viridian Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 1797 to 3342.

Explain Quick Ratio?
How much Cash & cash equivalents VRDN�s has?
What are VRDN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 4
Healthcare Sector	# 135
Within the Market	# 3342

trailing twelve months Quick Ratio Statistics
High	Average	Low
20.18	8.32	0.73
(Mar 31 2024)		(Dec 31 2016)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Medical Laboratories Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Aclarion Inc	19.27	$ 19.005 Millions	$ 0.986 Millions
Celcuity Inc	15.85	$ 387.064 Millions	$ 24.427 Millions
Maxcyte inc	12.09	$ 106.854 Millions	$ 8.838 Millions
Viridian Therapeutics Inc	11.31	$ 585.835 Millions	$ 51.805 Millions
Billiontoone Inc	9.40	$ 537.450 Millions	$ 57.162 Millions
Omniab Inc	7.34	$ 49.072 Millions	$ 6.685 Millions
Absci Corp	7.09	$ 125.705 Millions	$ 17.723 Millions
Personalis Inc	5.97	$ 233.218 Millions	$ 39.045 Millions
Castle Biosciences Inc	5.37	$ 261.685 Millions	$ 48.761 Millions
Veracyte Inc	5.16	$ 263.136 Millions	$ 51.019 Millions
Butterfly Network Inc	5.08	$ 137.954 Millions	$ 27.153 Millions
Guardant Health Inc	3.77	$ 1,102.760 Millions	$ 292.145 Millions
Bionexus Gene Lab Corp	3.30	$ 2.627 Millions	$ 0.797 Millions
Fulgent Genetics Inc	3.07	$ 276.302 Millions	$ 90.134 Millions
Caredx Inc	2.36	$ 187.176 Millions	$ 79.153 Millions
Incyte Corporation	2.32	$ 3,461.114 Millions	$ 1,489.649 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.